Clinical trials
Hyperlipidemias trials in China with no applicable phase
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
20 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2008 | 1 |
| 2014 | 1 |
| 2015 | 1 |
| 2018 | 2 |
| 2020 | 2 |
| 2021 | 1 |
| 2022 | 1 |
| 2023 | 3 |
| 2024 | 4 |
| 2025 | 3 |
| 2026 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Unknown status | 7 |
| Completed | 6 |
| Recruiting | 4 |
| Not yet recruiting | 2 |
| Active, not recruiting | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| China National Center for Cardiovascular Diseases | 2 |
| Shanghai 10th People's Hospital | 2 |
| Zhejiang University | 2 |
| AstraZeneca | 1 |
| Beijing Chao Yang Hospital | 1 |
| First Affiliated Hospital Xi'an Jiaotong University | 1 |
| First Affiliated Hospital of Jinan University | 1 |
| Guangdong Provincial Hospital of Traditional Chinese Medicine | 1 |
| Huazhong University of Science and Technology | 1 |
| Nanjing First Hospital, Nanjing Medical University | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Hyperlipidemias | 20 |
| Hypertension | 3 |
| Hyperglycemia | 2 |
| Obesity | 2 |
| Acute Coronary Syndrome | 1 |
| Breast Neoplasms | 1 |
| Carotid Artery Diseases | 1 |
| Diabetes Mellitus | 1 |
| Diabetes Mellitus, Type 2 | 1 |
| Dyslipidemias | 1 |
Trials
Showing 1 to 20 of 20. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.